Market Place
Sourcing Support
Drug developer 9 Meters Biopharma files for bankruptcy protection
18 Jul 2023 //
REUTERS
9 Meters Biopharma Announces Management Change Vurolenatide
30 May 2023 //
ACCESSWIRE
9 Meters Biopharma Provides Business Update & Reports FYR for 1Q 2023
15 May 2023 //
ACCESSWIRE
9 Meters Announces Pre-IND Meeting with FDA Regarding NM-136 for Obesity
05 Apr 2023 //
ACCESSWIRE
9 Meters Reports Financial Results for Fourth Quarter and Full Year 2022
28 Mar 2023 //
ACCESSWIRE
9 Meters Announces $5M Registered Direct Offering Priced at-the-Market
14 Mar 2023 //
ACCESSWIRE
9 Meters to Present at the Oppenheimer 33rd Annual Healthcare Conference
07 Mar 2023 //
ACCESSWIRE
9 Meters Biopharma Announces Continued Immuno-Oncology Collaboration
14 Nov 2022 //
ACCESSWIRE
9 Meters Biopharma Provides Business Update&Reports Financial Results for3Q 2022
08 Nov 2022 //
ACCESSWIRE
9 Meters Biopharma Presents Preclinical Data on GIP Monoclonal Antibodies
24 Oct 2022 //
ACCESSWIRE
9 Meters Biopharma to Present at the (ACG) 2022 Annual Scientific Meeting
18 Oct 2022 //
ACCESSWIRE
9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT
26 Sep 2022 //
ACCESSWIRE
9 Meters Biopharma to Present at the H.C. Wainwright 24th AnnualGIC
06 Sep 2022 //
ACCESSWIRE
9 Meters Biopharma to Participate at the 44th European Society
01 Sep 2022 //
ACCESSWIRE
9 Meters Biopharma to Participate in the Citi 17th Annual BioPharma Conference
31 Aug 2022 //
ACCESSWIRE
9 Meters Biopharma Reports Financial Results for Second Quarter 2022
15 Aug 2022 //
ACCESSWIRE
9 Meters and Cara tout mid-stage data for gastrointestinal, pruritus studies
30 Jun 2022 //
ENDPTS
9 Meters Announces Positive Preliminary Results from PII Study of Vurolenatide
30 Jun 2022 //
ACCESSWIRE
9 Meters Announces Debt Facility to Support PIII Study of Vurolenatide for SBS
30 Jun 2022 //
ACCESSWIRE
9 Meters’ celiac drug doesn’t measure up in phase 3
21 Jun 2022 //
FIERCEBIOTECH
9 Meters Biopharma & Celiac.com Announce Collaboration to Support Clinical TriaL
21 Apr 2022 //
CELIAC
9 Meters Biopharma Announces Allowance of Patent for Anti-GIP MAb NM-136
13 Apr 2022 //
ACCESSWIRE
9 Meters Biopharma, Inc. Announces Immuno-Oncology Collaboration with Gustave
10 Nov 2021 //
BIOSPACE
9 Meters Biopharma Appoints Samantha Ventimiglia to Board of Directors
04 Oct 2021 //
BIOSPACE
9 Meters Biopharma Announces Collaboration with EBRIS Foundation
16 Aug 2021 //
YAHOO
9 Meters Biopharma Provides Business Update and Reports for Second Quarter
12 Aug 2021 //
ACCESSWIRE
9 Meters Announces Initiation of Phase 2 VIBRANT Study of Vurolenatide
14 Jun 2021 //
ACESSWIRE
9 Meters Biopharma, Announces Publication in Journal of Clinical Investigation
26 May 2021 //
BIOSPACE
9 Meters Biopharma, Inc. Announces Collaboration with the Duke Clinical Research
19 Apr 2021 //
BIOSPACE
9 Meters Biopharma, Inc. and Celiac Disease Foundation Announce Collaboration
13 Apr 2021 //
BIOSACE
9 Meters Biopharma Announces Proposed Public Offering of Common Stock
30 Mar 2021 //
ACCESSWIRE
9 Meters Biopharma Announces Agreement with the (EBRIS)
21 Dec 2020 //
BIOSPACE
9 Meters Biopharma, Inc. Announces Closing of Offering of Common Stock
15 Dec 2020 //
ACCESSWIRE
9 Meters Biopharma, Inc. Announces Proposed Public Offering of Common Stock
10 Dec 2020 //
ACCESSWIRE
9 Meters Biopharma, Inc. Announces Positive Topline Data for NM-002
07 Dec 2020 //
NASDAQ
9 Meters Biopharma, Inc. Doses the First Patients in Ph 1b/2a Trial
21 Jul 2020 //
BIOSPACE
